Cappell, Mitchell S. http://orcid.org/0000-0003-3445-5428
Stavropoulos, Stavros Nicholas http://orcid.org/0000-0003-1410-2684
Friedel, David http://orcid.org/0000-0001-8051-7410
Article History
Received: 24 January 2019
Accepted: 7 August 2019
First Online: 27 August 2019
Compliance with Ethical Standards
:
: Dr. Cappell, Dr. Stavropoulos, and Dr. Friedel declare that they have no conflict of interest. In particular, Dr. Cappell, as a consultant of the United States Food and Drug Administration (FDA) Advisory Committee for Gastroenterology Drugs, affirms that this paper does not discuss any proprietary confidential pharmaceutical data submitted to the FDA and reviewed by Dr. Cappell. Dr. Cappell was until 1 year ago a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik. Dr. Cappell has had one-time consultancies for Mallinckrodt and Shire. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, Shire, or Mallinckrodt.